Ocular adnexal lymphomas: A review

Advances in Anatomic Pathology

Volumn 17, Issue 4, 2010, Pages 251-261

  McKelvie, Penelope A ^a  

^a ST VINCENT S HOSPITAL   (Australia)

Author keywords

immunohistochemistry; MALT lymphomas; molecular genetics; ocular adnexal lymphomas; staging; treatment

Indexed keywords

ANTIINFECTIVE AGENT; B LYMPHOCYTE ANTIGEN; CD23 ANTIGEN; CHLORAMBUCIL; COMPLEMENT COMPONENT C3B RECEPTOR; COMPLEMENT COMPONENT C3D RECEPTOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; DOXYCYCLINE; FLUDARABINE; IBRITUMOMAB TIUXETAN; IMMUNOGLOBULIN G4; IMMUNOGLOBULIN HEAVY CHAIN; PREDNISONE; PROTEIN BCL 10; VINCRISTINE;

ADNEXA DISEASE; B LYMPHOCYTE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CHLAMYDIASIS; CHLAMYDOPHILA PSITTACI; CHROMOSOME TRANSLOCATION; CLINICAL FEATURE; CONJUNCTIVA DISEASE; CORNEA ULCER; CYTOGENETICS; DENDRITIC CELL; DISEASE ASSOCIATION; HISTOPATHOLOGY; HUMAN; IMMUNOPHENOTYPING; LYMPHOMA; MOLECULAR GENETICS; NONHUMAN; OCULAR ADNEXAL LYMPHOMA; OPTIC NERVE ATROPHY; OUTCOME ASSESSMENT; PARTIAL TRISOMY 3; PRIORITY JOURNAL; PROGNOSIS; RADIOIMMUNOTHERAPY; RETINOPATHY; REVIEW; TRISOMY 18;

CYTOGENETIC ANALYSIS; EYE NEOPLASMS; HUMANS; LYMPHOMA; LYMPHOMA, B-CELL, MARGINAL ZONE; PSITTACOSIS; TREATMENT OUTCOME;

EID: 77954489482     PISSN: 10724109     EISSN: 15334031     Source Type: Journal    
DOI: 10.1097/PAP.0b013e3181e4abdb     Document Type: Review

References (115)

1. Bairey O, Kremer I, Rakowsky E, et al. Orbital and adnexal involvement in systemic non-Hodgkin's lymphoma. Cancer. 1994;73:2395-2399. (Pubitemid 24129125)
2. Freeman C, Berg JW, Cutler SJ. Occurrence and prognosis of extranodal lymphoma. Cancer. 1972;29:252-260.
3. Moslehi R, Devesa SS, Schairer C, et al. Rapidly increasing incidence of ocular non-Hodgkin lymphoma. J Natl Cancer Inst. 2006;98:936-939. (Pubitemid 44018924)
4. Stefanovic A, Lossos IS. Extranodal marginal zone lympho-ma of the ocular adnexa. Blood. 2009;114:501-510.
5. Decaudin D, de Cremoux P, Vincent-Salomon A, et al. Ocular adnexal lymphoma: a review of clinicopathologic features and treatment options. Blood. 2006;108:1451-1460. (Pubitemid 44316108)
6. Knowles DM, Jakobiec FA, McNally L, et al. Lymphoid hyperplasia and malignant lymphoma occurring in the ocular adnexa (orbit, conjunctiva and eyelids): a prospective multi-parametric analysis of 108 cases during 1977 to 1987. Hum Pathol. 1990;21:959-973.
7. Johnson TE, Tse DT, Byrne GE Jr. Ocular adnexal lymphoid tumors: a clinicopathologic and molecular genetic study of 77 patients. Ophthal Plast Reconstr Surg. 1999;15:171-179.
8. White WL, Ferry JA, Harris NL, et al. Ocular adnexal lymphoma. A clinicopathologic study with identification of mucosa-associated lymphoid tissue type. Ophthalmology. 1995;102:1994-2006.
9. Coupland SE, Krause L, Delecluse HJ, et al. Lymphoproli-ferative lesions of the ocular adnexa. Ophthalmology. 1998; 105:1430-1441.
10. Jenkins C, Rose GE, Bunce C, et al. Histological features of ocular adnexal lymphoma (REAL classification) and their association with patient morbidity and survival. Br J Ophthalmol. 2000;84:907-913. (Pubitemid 30599102)
11. McKelvie PA, McNab A, Francis IC, et al. Ocular adnexal lymphoproliferative disease: a series of 73 cases. Clin Exp Ophthalmol. 2001;29:387-393. (Pubitemid 34036740)
12. Fung CY, Tarbell NJ, Lucarelli MJ, et al. Ocular adnexal lymphoma: clinical behaviour of distinct world Health Organization classification subtypes. Int J Radiat Oncol Biol Phys. 2003;57:1382-1391.
13. Meunier J, Lumbroso-le Rouic L, Vincent-Salomon A, et al. Ophthalmologic and intraocular non-Hodgkins lymphoma: a large single centre study of initial characteristics, natural history and prognostic factors. Hematol Oncol. 2004;22: 143-158. (Pubitemid 41342406)
14. Sullivan TJ, Whitehead K, Williamson R, et al. Lymphopro-liferative disease of the ocular adnexa: a clinical and pathologic study with statistical analysis of 69 patients. Ophthal Plast Reconstr Surg. 2005;21:177-188. (Pubitemid 40847475)
15. Auw-Haedrich C, Coupland S, Kapp A, et al. Long term outcome of ocular adnexal lymphoma subtyped according to the REAL classification. Br J Ophthalmol. 2001;85: 63-69. (Pubitemid 32060197)
16. Coupland SE, Hellmich M, Auw-Hedrich C, et al. Prognostic value of cell-cycle markers in ocular adnexal lymphoma: an assessment of 230 cases. Graefes Arch Clin Exp Ophthalmol. 2004;42:130-145. (Pubitemid 38324966)
17. Coupland SE, Hellmich M, Auw-Haedrich C, et al. Plasma-cellular differentiation in extranodal marginal zone B-cell lymphomas of the ocular adnexa: an analysis of the neoplastic plasma cell phenotype and its prognostic significance in 136 cases. Br J Ophthalmol. 2005;89:352-359. (Pubitemid 40327622)
18. Cho EY, Han JJ, Ree HJ, et al. Clinicopathologic analysis of ocular adnexal lymphomas: extranodal marginal zone B-cell lymphoma constitutes the vast majority of ocular lymphomas among Koreans and affects younger patients. Am J Hematol. 2003;73:87-96.
19. Ferry JA, Fung CY, Zukerberg L, et al. Lymphoma of the ocular adnexa: a study of 353 cases. Am J Surg Pathol. 2007; 31:170-184. (Pubitemid 46175017)
20. Tanimoto K, Kaneko A, Suzuki S, et al. Primary ocular adnexal lymphoma: a long-term follow-up of 114 patients. Jpn J Clin Oncol. 2007;37:337-344. (Pubitemid 47248951)
21. Mannami T, Yoshino T, Oshima K, et al. Clinical, histopathological and immunogenetic analysis of ocular adnexal lymphoproliferative disorders: characterization of MALT lymphoma and reactive lymphoid hyperplasia. Mod Pathol. 2001;14:641-649. (Pubitemid 32667207)
22. Yoon JS, Ma KT, Kim SJ, et al. Prognosis for patients in a Korean population with ocular adnexal lymphoproliferative lesions. Ophthal Plast Reconstr Surg. 2007;23:94-99.
23. Coupland SE, Foss H-D, Assaf C, et al. T-cell and T/natural killer-cell lymphomas involving ocular and ocular adnexal tissues. Ophthalmology. 1999;106:2109-2120.
24. Sharara N, Holden JT, Wojno TH, et al. Ocular adnexal lymphoid proliferations. Clinical, histologic, flow cytometric and molecular analysis of 43 cases. Ophthalmology. 2003;110: 1245-1254. (Pubitemid 36676662)
25. Demirci H, Shields CL, Karatza EC, et al. Orbital lymph-proliferative tumors: analysis of clinical features and systemic involvement in 160 cases. Ophthalmology. 2008;115: 1626-1631.
26. Margo CE, Mulla ZD. Malignant tumors of the orbit. Analysis of the Florida cancer registry. Ophthalmology. 1998;105:185-190.
27. Isaacson PG, Chott A, Nakamura S, et al. Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). In: Swerdlow SH, Campo E, Harris NL, eds. WHO classification of Tumours of the Haemopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2008:214-217.
28. Schiby G, Polak-Charcon S, Mardoukh C, et al. Orbital marginal zone lymphomas: an immunohistochemical, poly-merase chain reaction and fluorescence in situ hybridization study. Hum Pathol. 2007;38:435-442. (Pubitemid 46227531)
29. Lagoo AS, Haggerty C, Kim Y, et al. Morphologic features of 115 lymphomas of the orbit and ocular adnexa categorized according to the World Health Organization classification. Arch Pathol Lab Med. 2008;132:1405-1416.
30. Jakobiec FA. Ocular adnexal lymphoid tumors. Progress in need of clarification. Am J Ophthalmol. 2008;145:941-950.
31. Ferry JA, Yang WI, Zukerberg L, et al. CD5+ extranodal marginal zone B-cell lymphoma: a low grade neoplasm with a propensity for bone marrow involvement and relapse. Am J Clin Pathol. 1996;105:31-37. (Pubitemid 26024765)
32. Mozos A, Royo C, Hartmann E, et al. SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Haematologica. 2009;94:1555-1562.
33. Ferreri AJM, Dolcetti R, Du M-Q, et al. Ocular adnexal MALT lymphoma: an intriguing model for antigen-driven lymphomagenesis and microbial-targeted therapy. Ann Oncol. 2008;19:835-846. (Pubitemid 351627298)
34. Ruiz A, Reischl U, Swerdlow SH, et al. Extranodal marginal zone lymphomas of the ocular adnexa. Multiparameter analysis of 34 cases including interphase molecular cyto-genetics and PCR for Chlamydia psittaci. Am J Surg Pathol. 2007;31:792-802. (Pubitemid 46684221)
35. Rosado MF, Byrne GE Jr, Ding F, et al. Ocular adnexal lymphoma: a clinicopathologic study of a large cohort study of patients with no evidence for an association with Chlamydia psittaci. Blood. 2006;107:467-472. (Pubitemid 43076366)
36. Adachi A, Tamaru J-i, Kaneko K, et al. No evidence of correlation between BCL10 expression and API2-MALT1 gene rearrangement in ocular adnexal MALT lymphoma. Path Intern. 2004;54:16-25. (Pubitemid 38979577)
37. White VA, Gascoyne RD, McNeil BK, et al. Histopathologic findings and frequency of clonality by the polymerase chain reaction in ocular adnexal lymphoproliferative lesions. Mod Pathol. 1996;9:1052-1061.
38. Chen PM, Chiou TJ, Yu IT, et al. Molecular analysis of mucosa-associated lymphoid tissue (MALT) lymphoma of the ocular adnexa. Leuk Lymphoma. 2001;42:207-214.
39. Sigurdardottir M, Sigurdson H, Bargadottir RB, et al. Lymphoid tumours of the ocular adnexa: a morphologic and genotypic study of 15 cases. Acta Ophthalmol Scand. 2003;8:299-1203 (Pubitemid 36806271)
40. Marshall-Taylor CE, Cartun RW, Mandich D, et al. Immunohistochemical detection of immunoglobulin light chain expression in B-cell non-Hodgkin's lymphomas using formalin-fixed paraffin-embedded tissues and a heat-induced epitope retrieval technique. Appl Immunohistochem Mol Morphol. 2002;10:258-262. (Pubitemid 34988536)
41. Gruenberger B, Woehrer S, Troch M, et al. Assessment of the role of hepatitis C, Helicobacter pylori and autoimmunity in MALT lymphoma of the ocular adnexa in 45 Austrian patients. Acta Oncologica. 2008;47:355-359. (Pubitemid 351414918)
42. Tanimoto K, Sekiguchi N, Yokota Y, et al. Fluorescence in situ hybridization (FISH) analysis of primary ocular adnexal MALT lymphoma. BMC Cancer. 2006;6:249. (Pubitemid 44696824)
43. Remstein ED, Dogan A, Emerson RR, et al. The incidence and anatomic site specificity of chromosomal translocations in primary extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoma tissue (MALT lymphoma) in north America. Am J Surg Pathol. 2006;30:1546-1553. (Pubitemid 44815508)
44. Takada S, Yoshino T, Taniwaki M, et al. Involvement of the chromosomal translocation t(11,18) in some mucosa-asso-ciated lymphoid tissue lymphomas and diffuse large B-cell lymphomas of the ocular adnexa. Evidence from multiplex reverse transcriptase-polymerase chain reaction and fluorescence in situ hybridization using formalin-fixed paraffin-embedded specimens. Mod Pathol. 2003;16:445-462. (Pubitemid 36618465)
45. Streubel B, Simonitsch-Klupp I, Muellauer L, et al. Variable frequencies of MALT lymphoma-associated genetic aberrations in MALT lymphomas of different sites. Leukemia. 2004;18:1722-1726. (Pubitemid 39386353)
46. Streubel B, Lamprecht A, Dierlamm J, et al. T(14;18) (q32;q21) involving IGH and MALT1 is a frequent chromosomal aberration in MALT lymphoma. Blood. 2003;101: 2335-2339. (Pubitemid 36302078)
47. Raderer M, Wohrer S, Streubel B, et al. Assessment of disease dissemination in gastric compared with extragastric mucosa-associated lymphoid tissue lymphoma using extensive staging: a single-center experience. J Clin Oncol. 2006;24:3136-3141. (Pubitemid 46646224)
48. Ye H, Liu H, Attygalle A, et al. Variable frequency of t(11;18(q21;q21) in MALT lymphomas of different sites: significant association with CagA strains of H.pylori in gastric MALT lymphoma. Blood. 2003;101:2335-2339. (Pubitemid 36917798)
49. Du M-Q. MALT lymphoma: recent advances in aetiology and molecular genetics. J Clin Exp Hematopathol. 2007;47: 31-42.
50. Nakamura S, Ye H, Bacon CM, et al. Clinical impact of genetic aberrations in gastric MALT lymphoma: a comprehensive analysis using interphase fluorescence in situ hybridisation. Gut. 2007;56:1358-1363. (Pubitemid 47517827)
51. Cook JR, Sherer M, Craig FE, et al. T(14;18)(q32;q21) involving MALT1 and IGH genes in an extranodal diffuse large B-cell lymphoma. Hum Pathol. 2003;34:1212-1215. (Pubitemid 37467008)
52. Ye H, Gong L, Liu H, et al. MALT lymphoma with t(14;18)(q32;q21)/IGH- MALT1 is characterized by strong cytoplasmic MALT1 and BCL10 expression. J Pathol. 2005; 205:293-301. (Pubitemid 40253919)
53. Streubel B, Vinatzer U, Lamprecht A, et al. T(3;14)(p14.1;q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma. Leukemia. 2005;19:652-658. (Pubitemid 40521171)
54. Goatly A, Bacon CM, Nakamura S, et al. FOXP1 abnormalities in lymphoma: translocation breakpoint mapping reveals insights into deregulated transcriptional control. Mod Pathol. 2008;21:902-911. (Pubitemid 351896666)
55. Vinatzer U, Gollinger M, Mullauer L, et al. Mucosa-associated lymphoid tissue lymphoma: novel translocations involving ODZ2, JMJD2C and CNN3. Clin Canc Res. 2008;14:6426-6431.
56. Ye HT, Dogan A, Karran L, et al. BCL10 expression in normal and neoplastic lymphoid tissue-nuclear localization in MALT lymphoma. Am J Pathol. 2000;157:1147-1154.
57. Sagaert X, Laurent M, Baens M, et al. MALT1 and BCL10 aberrations in MALT lymphomas and their effect on the expression of BCL10 in the tumour cells. Mod Pathol. 2006; 19:225-232. (Pubitemid 43117606)
58. Merzianu M, Jiang L, Lin P, et al. Nuclear BCL10 expression is common in lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia and does not correlate with p65 NF-kB activation. Mod Pathol. 2006;19:891-898. (Pubitemid 43910467)
59. Ferreri A, Guidoboni M, Ponzoni M, et al. Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas. J Natl Cancer Inst. 2004;19:1315-1326. (Pubitemid 38584982)
60. Ferreri AJ, Ponzoni M, Guidoboni M, et al. Regression of ocular adnexal lymphoma after Chlamydia psittaci-eradicat-ing antibiotic therapy. J Clin Oncol. 2005;23:5067-5073. (Pubitemid 46224014)
61. Ferreri AJ, Ponzoni M, Dognini GP, et al. Bacteria eradicating therapy for ocular adnexal lymphoma: questions for an open international prospective trial. Ann Oncol. 2006; 17:1721-1722. (Pubitemid 44680897)
62. Ferreri AJM, Ernberg I, Copie-Bergman C. Infectious agents and lymphoma development: molecular and clinical aspects. J Intern Med. 2009;265:421-438.
63. Chanudet E, Zhou Y, Bacon CM, et al. Chlamydia psittaci is variably associated with ocular adnexa MALT lymphoma in different geographical regions. J Pathol. 2006;209:344-351. (Pubitemid 43997743)
64. Husain A, Roberts D, Pro B, et al. Meta-analyses of the association between Chlamydia psittaci and ocular adnexal lymphoma and the response of ocular adnexal lymphoma to antibiotics. Cancer. 2007;110:809-815. (Pubitemid 47257658)
65. Decaudin D, Dolcetti R, De Cremoux P, et al. Variable association between Chlamydia psittaci infection and ocular adnexal lymphomas: methodological biases or true geographical variations. Anti-cancer Drugs. 2008;19:761-765.
66. Cheuk W, Yuen HKL, Chan ACL, et al. Ocular adnexal lymphoma associated with IgG-4+ chronic sclerosing dacryoadenitis: a previously undescribed complication of IgG-4-related sclerosing disease. Am J Surg Pathol. 2008;32: 1159-1167.
67. Sato Y, Ohshima K, Ichimura K, et al. Ocular adnexal IgG4 related disease has uniform clinicopathology. Path Intern 2008;58:465-470. (Pubitemid 351952020)
68. Jenkins C, Rose GE, Bunce C, et al. Clinical features associated with survival of patients with lymphoma of the ocular adnexa. Eye. 2003;17:809-820. (Pubitemid 37337033)
69. Shields CL, Shields JA, Carvalho C, et al. Conjunctival lymphoid tumors. Clinical analysis of 117 cases and relationship to systemic lymphoma. Ophthalmology. 2001;108: 979-984. (Pubitemid 32374256)
70. Bessell EM, Henk JM, Wright JE, et al. Orbital and conjunctival lymphoma treatment and prognosis. Radiother Oncol. 1988;13:237-244.
71. Martinet S, Ozsahin M, Belkacemi Y, et al. Outcome and prognostic factors in orbital lymphoma: a rare cancer network study on 90 consecutive patients treated with radiotherapy. Int J Radiat Oncol Biol Phys. 2003;55: 892-898. (Pubitemid 36292130)
72. Nakata M, Matsumo Y, Katsumata N, et al. Histology according to the revised European American lymphoma classification significantly predicts the prognosis of ocular adnexal lymphoma. Leuk Lymphoma. 1999;32:533-543. (Pubitemid 29086368)
73. Gayed I, Eskandari MF, McLaughlin P, et al. Value of positron emission tomography in staging ocular adnexal lymphomas and evaluating their response to therapy. Ophthalmic Surg Lasers Imaging. 2007;38:319-325. (Pubitemid 47280431)
74. Sullivan TJ, Valenzuela AA. Imaging features of ocular adnexal lymphoproliferative disease. Eye. 2006;20:1189-1195. (Pubitemid 44515581)
75. Valenzuela AA, Allen C, Grimes D, et al. Positron emission tomography in the detection and staging of ocular adnexal lymphoproliferative disease. Ophthalmology. 2006;113: 2331-2337. (Pubitemid 44848369)
76. Hoffman M, Woehrer S, Becherer A, et al. 18-Fluoro-deoxy-glucose positron emission tomography in lymphoma of mucosa-associated lymphoid tissue: histology makes the difference. Ann Oncol. 2006;17:1761-1765. (Pubitemid 44884049)
77. Carbone PP, Kaplan HS, Musshoff K, et al. Report of the committee on Hodgkins disease staging classification. Cancer Res. 1971;31:1860-1861.
78. Coupland SE, White VA, Rootman J, et al. A TNM-based clinical staging system of ocular adnexal lymphomas. Arch Pathol Lab Med. 2009;133:1262-1267.
79. Coupland SE, White V, Rootman J, et al. TNM Staging of ocular adnexal lymphomas. In: Edge SE, Byrd DR, Carducci MA, et al, eds. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2009.
80. Roe RH, Finger PT, Kurli M, et al. Whole-body positron emission tomography/computed tomography imaging and staging of orbital lymphoma. Ophthalmology. 2006;113: 1854-1858. (Pubitemid 44442432)
81. Meunier J, Lumbroso-Le Rouic L, et al. Conjunctival low-grade non-Hodgkin's lymphoma: a large single-center study of initial characteristics, natural history and prognostic factors. Leuk Lymphoma. 2006;47:1295-1305. (Pubitemid 44269637)
82. Swerdlow SH, Campo E, Harris NL, eds. WHO Classification of Tumours of the Haemopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2008 10-13.
83. Esik O, Ikeda H, Mukai L, et al. A retrospective analysis of different modalities for treatment of primary orbital non-Hodgkin's lymphomas. Radiother Oncol. 1996;38:13-18. (Pubitemid 26042738)
84. Restrepo A, Raez LE, Byrne GE Jr, et al. Is central nervous system prophylaxis necessary in ocular adnexal lymphoma? Crit Rev Oncog. 1998;9:269-273. (Pubitemid 29102649)
85. Lee J-Y, Kim M-K, Lee K-H, et al. Extranodal marginal zone B-cell lymphomas of mucosa-associated lymphoid tissue-type of the orbit. Ann Hematol. 2005;84:12-18.
86. Tanimoto K, Kaneko A, Suzuki S, et al. Long-term follow-up results of no initial therapy for ocular adnexal MALT lymphoma. Ann Oncol. 2006;17:135-140. (Pubitemid 43033853)
87. Bhatia S, Paulino AC, Buatti JM, et al. Curative radiotherapy for primary orbital lymphoma. Int J Radiat Oncol Biol Phys. 2002;54:818-823.
88. Liao SL, Kao SC, Chou PK, et al. Results of radiotherapy for orbital and adnexal lymphoma. Orbit. 2002;21:117-123. (Pubitemid 34620824)
89. Le QT, Eulau SM, George TI, et al. Primary radiotherapy for localized MALT lymphoma. Int J Radiat Oncol Biol Phys. 2002;52:657-663. (Pubitemid 34158727)
90. Uno T, Isobe K, Shikama N, et al. Radiotherapy for extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue originating in the ocular adnexa. Cancer. 2003;98:865-871.
91. Tsang RW, Gospodarowicz ML, Pintilie M, et al. Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome. J Clin Oncol. 2001;21:4157-4164. (Pubitemid 46606184)
92. Letschert JG, Gonzalez Gonzalez D, Oskam J, et al. Results of radiotherapy in patients with stage I orbital non-Hodgkin's lymphoma. Radiother Oncol. 1991;22:36-44.
93. Chao CK, Lin HS, Devineni VR, et al. Radiation therapy for primary ocular lymphoma. Int J Radiat Oncol Biol Phys. 1995;31:929-934.
94. Bolek TW, Moyses HM, Marcus RB Jr. Radiotherapy in the management of orbital lymphoma. Int J Radiat Oncol Biol Phys. 1999;44:31-36.
95. Hasegawa M, Kojima M, Shioya M, et al. Treatment results of radiotherapy for malignant lymphoma of the orbit and histopathologic review according to the WHO classification. Int J Radiat Oncol Biol Phys. 2003;55:892-898. (Pubitemid 36959753)
96. Durkin SR, Roos D, Higgs B, et al. Ophthalmic and adnexal complications of radiotherapy. Acta Ophthalmol Scand. 2007; 85:240-250. (Pubitemid 46711359)
97. Erkal HS, Serin M, Sak SD, et al. Radiation therapy for stage I primary orbital non-Hodgkin's lymphomas. Tumori. 1997; 83:822-825. (Pubitemid 28067103)
98. Stafford SL, Kozelsky TF, Garrity JA, et al. Orbital lymphoma: radiotherapy outcome and complications. Radio-ther Oncol. 2001;59:139-144.
99. Ben Simon GJ, Cheung N, McKelvie P, et al. Oral chlorambucil for extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue of the orbit. Ophthal-mol. 2006;113:1209-1213. (Pubitemid 43947228)
100. Charlotte F, Doghmi K, Cassoux N, et al. Ocular adnexal marginal zone lymphoma: a clinical study and pathologic study of 23 cases. Virchows Archiv. 1002;448:506-516.
101. Song EK, Kim SY, Kim TM, et al. Efficacy of chemotherapy as first-line treatment in ocular adnexal extranodal marginal zone B-cell lymphoma. Ann Oncol. 2008;19:242-246.
102. Galieni P, Polito E, Leccisotti A, et al. Localized orbital lymphoma. Haematologica. 1997;82:436-439. (Pubitemid 28023281)
103. Rigacci L, Nassi L, puccioni M, et al. Rituximab and chlorambucil as first-line treatment for low grade ocular adnexal lymphomas. Ann Hematol. 2007;86:565-568. (Pubitemid 47018474)
104. Conconi A, Martinelli G, Thieblemont C, et al. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood. 2003;102:2741-2745. (Pubitemid 37248842)
105. Raderer M, Jager G, Brugeri S, et al. Rituximab for treatment of advanced marginal zone lymphoma of the mucosa associated lymphoid tissue lymphoma. Oncology. 2003;65: 306-310. (Pubitemid 38064941)
106. Lossos IS, Morgensztern D, Blaya M, et al. Rituximab for treatment of chemoimmunotherapy naive marginal zone lymphoma. Leuk Lymphoma. 2007;48:1630-1632. (Pubitemid 47272814)
107. Nuckel H, Meller D, Steuhl KP, et al. Anti-CD20 monoclonal antibody therapy in relapsed MALT lymphoma of the conjunctiva. Eur J Hematol. 2004;73:258-262. (Pubitemid 39294690)
108. Ferreri AJ, Ponzoni M, Martinelli G, et al. Rituximab in patients with mucosa-associated lymphoid tissue type lymphoma of the ocular adnexa. Haematologica. 2005;90: 1578-1579. (Pubitemid 41658773)
109. Benetatos L, Alymara V, Asproudis I, et al. Rituximab as first line treatment for MALT lymphoma of the extraocular muscle. Ann Hematol. 2006;85:625-626. (Pubitemid 44283085)
110. Heinz C, Merz H, Nieschalk M, et al. Rituximab for the treatment of extranodal marginal zone lymphoma of the lacrimal gland. Br J Ophthalmol. 2007;91:1563-1564. (Pubitemid 350044070)
111. Esmaeili B, McLaughlin P, Pro B, et al. Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiux-etan (Zevalin) for frontline treatment of early stage extra-nodal indolent ocular adnexal lymphoma. Ann Oncol. 2009;20:709-714.
112. Shome D, Esmaeli B. Targeted monoclonal antibody therapy and radioimmunotherapy for lymphoproliferative disorders of the ocular adnexa. Curr Opin Opthalmol. 2008;19:414-421.
113. Gruenberger B, Woeher S, Streubel B, et al. Antibiotic treatment is not effective in patients infected with Helicobacter pylori suffering from extragastric MALT Lymphoma. J Clin Oncol. 2006;24:1370-1375. (Pubitemid 46622000)
114. Zucca E, Conconi A, Pedrinis E, et al. Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood. 2003;101:2489-2495. (Pubitemid 36857603)
115. Tasaki K, Shichishima A, Furuta M, et al. CD5-positive mucosa associated lymphoid tissue (MALT) lymphoma of ocular adnexal origin: usefulness of fluorescence in situ hybridization for distinction between mantle cell lymphoma and MALT lymphoma. Pathol Int. 2007;57:101-107. (Pubitemid 46252839)